|117.25||+1.24||+1.07%||Vol 4.64M||1Y Perf 45.54%|
|Mar 5th, 2021 16:02 DELAYED|
|- -||0.25 0.21%|
|Target Price||128.92||Analyst Rating||Strong Buy 1.44|
|Potential %||9.95||Finscreener Ranking||★★★ 50.15|
|Insiders Trans % 3/6/12 mo.||-89/-92/-95||Value Ranking||★★ 47.64|
|Insiders Value % 3/6/12 mo.||-99/-99/-100||Growth Ranking||★★★★+ 64.72|
|Insiders Shares Cnt. % 3/6/12 mo.||-99/-99/-100||Income Ranking||★★+ 43.02|
|Market Cap||207.71B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||83.13||Earnings Date||15th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||15th Apr 2021|
|Estimated EPS Next Report||1.34|
|EPS Growth Next 5 Years %||14.10|
|Avg. Weekly Volume||4.65M|
|Avg. Monthly Volume||4.53M|
|Avg. Quarterly Volume||5.03M|
Abbott Laboratories (NYSE: ABT) stock closed at 117.25 per share at the end of the most recent trading day (a 1.07% change compared to the prior day closing price) with a volume of 4.86M shares and market capitalization of 207.71B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.
The one-year performance of Abbott Laboratories stock is 45.54%, while year-to-date (YTD) performance is 7.09%. ABT stock has a five-year performance of 199.26%. Its 52-week range is between 61.61 and 128.54, which gives ABT stock a 52-week price range ratio of 83.13%
Abbott Laboratories currently has a PE ratio of 47.90, a price-to-book (PB) ratio of 6.47, a price-to-sale (PS) ratio of 6.26, a price to cashflow ratio of 27.10, a PEG ratio of 2.32, a ROA of 6.14%, a ROC of 7.60% and a ROE of 13.49%. The company’s profit margin is 12.85%, its EBITDA margin is 25.50%, and its revenue ttm is $34.61 Billion , which makes it $19.54 revenue per share.
Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.34 for the next earnings report. Abbott Laboratories’s next earnings report date is 15th Apr 2021.
The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.44), with a target price of $128.92, which is +9.95% compared to the current price. The earnings rating for Abbott Laboratories stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abbott Laboratories has a dividend yield of 1.47% with a dividend per share of $1.80 and a payout ratio of 74.00%.
Abbott Laboratories has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.64, ATR14 : 3.33, CCI20 : -170.69, Chaikin Money Flow : 0.06, MACD : 0.11, Money Flow Index : 20.39, ROC : -6.51, RSI : 42.63, STOCH (14,3) : 18.24, STOCH RSI : 0.22, UO : 42.82, Williams %R : -81.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Option Excercise at a value of $1 152 000), Andrea F. Wainer (Sold 34 237 shares of value $3 655 189 ), Andrew H. Lane (Option Excercise at a value of $3 505 313), Andrew H. Lane (Sold 80 000 shares of value $7 360 104 ), Charles R. Brynelsen (Sold 1 002 shares of value $120 851 ), Christopher J. Scoggins (Option Excercise at a value of $2 017 200), Christopher J. Scoggins (Sold 45 414 shares of value $5 585 585 ), Daniel Gesua Sive Salvadori (Option Excercise at a value of $1 996 513), Daniel Gesua Sive Salvadori (Sold 44 143 shares of value $4 952 396 ), Gregory A. Ahlberg (Sold 1 052 shares of value $126 882 ), Hubert L. Allen (Option Excercise at a value of $7 887 902), Hubert L. Allen (Sold 203 393 shares of value $25 113 251 ), Jaime Contreras (Option Excercise at a value of $6 192 994), Jared L. Watkin (Sold 1 391 shares of value $167 769 ), John F. Ginascol (Option Excercise at a value of $5 538 464), John F. Ginascol (Sold 63 552 shares of value $6 109 505 ), John M. Capek (Option Excercise at a value of $2 535 691), John M. Capek (Sold 102 400 shares of value $10 653 603 ), Joseph J. Manning (Option Excercise at a value of $720 000), Joseph J. Manning (Sold 21 880 shares of value $2 687 347 ), Lisa D. Earnhardt (Sold 1 815 shares of value $192 951 ), Mary K. Moreland (Sold 905 shares of value $113 621 ), Michael D. Dale (Sold 1 475 shares of value $177 900 ), Michael J. Pederson (Option Excercise at a value of $0), Michael J. Pederson (Sold 23 008 shares of value $2 254 784 ), Michelle A. Kumbier (Buy at a value of $249 900), Phebe N. Novakovic (Option Excercise at a value of $700 784), Phebe N. Novakovic (Sold 6 656 shares of value $701 901 ), Philip P. Boudreau (Sold 10 600 shares of value $869 200 ), Randel W. Woodgrift (Sold 7 258 shares of value $734 923 ), Robert E. Funck (Option Excercise at a value of $14 835 309), Robert E. Funck (Sold 249 999 shares of value $27 206 865 ), Roger M. Bird (Sold 7 403 shares of value $818 168 ), Roxanne S. Austin (Sold 13 688 shares of value $1 366 076 ), William A. Osborn (Option Excercise at a value of $935 991)
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.